AlphaMaven AlphaMaven

How do biotech hedge funds make money?

Reported by Worksinprogress
Nov 19, 2026· 3 min read
Save Post LinkedIn Email
Key Takeaways
  • • Biotech-focused hedge funds such as Baker Brothers Advisors, Deerfield Management, and OrbiMed each manage over $15 billion, according to the article, with dozens of smaller specialist funds beneath them.
  • • Insilico Medicine's inClinico platform predicted Phase II trial outcomes at 79 percent accuracy across 14 resolved trials, using date-stamped preprint publications made before readouts.
  • • Expert network consultations, priced at $500 to $1,000 or more per hour, are a standard research channel for biotech investors, and the article identifies them as the setting for the SAC Capital insider trading case.
  • • The SAC Capital case involved roughly $700 million in bapineuzumab positions and $275 million in combined profits and avoided losses, with Mathew Martoma convicted in 2014 and SAC paying $1.8 billion in fines.
  • • The article argues that accurate biotech pricing is a net benefit, while noting that a small number of managers may hold information others cannot reasonably access.
Summary
A Works in Progress essay examines how biotech hedge funds generate returns when clinical trial outcomes appear hard to forecast. The author notes that hundreds of billions of dollars are managed by hedge funds and investment firms specializing in biotech, led by Baker Brothers Advisors, Deerfield Management, and OrbiMed, each with more than $15 billion under management. The piece argues that many trial outcomes are more predictable than commonly assumed. Funds have historically paid graduate students to compile public information, and RA Capital maintains a division called TechAtlas for this purpose. The article cites Insilico Medicine's inClinico platform, which predicted Phase II outcomes at 79 percent accuracy across 14 resolved trials using target-choice and trial-design features.

The essay contends that public information alone does not explain consistent returns, and points to private information obtained through expert networks. Analysts pay $500 to $1,000 or more per hour to speak with clinicians and researchers. The author describes this practice as legal, while observing that the line between legitimate research and improper disclosure can be thin.

The article's central example is the SAC Capital case. Mathew Martoma, a portfolio manager at SAC Capital Advisors, connected through Gerson Lehrman Group with Dr. Sidney Gilman, a University of Michigan neurology professor who chaired the safety monitoring committee for bapineuzumab, an Alzheimer's drug. Over two years Martoma arranged dozens of paid consultations. SAC built a position of roughly $700 million in the drug's two sponsoring companies. After Gilman told Martoma in July 2008 that the drug was failing, SAC liquidated the position and went short, netting $275 million in combined profits and avoided losses when results were announced. Martoma was convicted of securities fraud in 2014, and SAC Capital paid $1.8 billion in fines and pleaded guilty to fraud charges before rebranding as Point72 Asset Management. According to the article, FINRA surveillance flagged the trading pattern, which led to SEC and FBI involvement and Gilman's cooperation.

The author concludes that such cases are edge cases and that accurate biotech pricing is socially valuable. The essay cites Baker Brothers' investment in Seagen, which reportedly turned $2 billion into $10 billion over twenty years, as evidence of prescient positioning, while suggesting that some managers benefit from information others cannot reasonably obtain.

Go deeper than the headline

Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.

Start your free 7-day trial

Sources

1 outlet

AlphaMaven summarised this story from the reporting below. Each link opens the original article.

Worksinprogress How do biotech hedge funds make money?